- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04363684
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Study Overview
Status
Conditions
- Amyotrophic Lateral Sclerosis
- Progressive Supranuclear Palsy (PSP)
- Corticobasal Degeneration (CBD)
- GRN Related Frontotemporal Dementia
- Behavioral Variant Frontotemporal Dementia (bvFTD)
- Semantic Variant Primary Progressive Aphasia (svPPA)
- Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
- FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)
- Oligosymptomatic PSP (oPSP)
- Frontotemporal Lobar Degeneration (FTLD)
- C9orf72
- MAPT Gene Mutation
- TBK1 Gene Mutation
- Oligosymptomatic Progressive Supranuclear Palsy
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Leah K Forsberg, PhD
- Phone Number: 507-293-9577
- Email: forsberg.leah@mayo.edu
Study Contact Backup
- Name: Hilary Heuer, PhD
- Phone Number: 415-476-6743
- Email: hilary.heuer@ucsf.edu
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada
- Recruiting
- University of British Columbia
-
Contact:
- Jessica Luk
- Email: jessica.luk@vch.ca
-
Contact:
- Rachel Freid
- Phone Number: 604-827-1050
- Email: rachel.freid@uhn.ca
-
Principal Investigator:
- Ging-Yuek Robin Hsiung, MD, MHSc, FRCPC
-
Principal Investigator:
- Ian Mackenzie, MD, MSc, LMCC, FRCPC
-
-
Ontario
-
Toronto, Ontario, Canada
- Recruiting
- University of Toronto
-
Principal Investigator:
- Carmela Tartaglia, MD, FRCPC
-
Contact:
- Kasey Cortez
- Email: kasey.cortez@uhn.ca
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- University of Alabama Birmingham
-
Contact:
- Loren Brown
- Email: samanthabrown@uabmc.edu
-
Principal Investigator:
- Erik Roberson, MD
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- University of California, Los Angeles
-
Principal Investigator:
- Mario Mendez, MD
-
Contact:
- Alexander Sheppard
- Email: asheppard@mednet.ucla.edu
-
San Diego, California, United States, 92093
- Recruiting
- University of California, San Diego
-
Contact:
- Michael Skipworth
- Email: mskipworth@health.ucsd.edu
-
Principal Investigator:
- Irene Litvan, MD
-
Principal Investigator:
- Doug Galasko, MD
-
Principal Investigator:
- Gabriel Leger, MD
-
Contact:
- Brandon Pulido
- Email: b1pulido@health.ucsd.edu
-
San Francisco, California, United States, 91358
- Recruiting
- University of California San Francisco
-
Contact:
- Dilanaz Unal
- Email: Dilanaz.Unal@ucsf.edu
-
Principal Investigator:
- Adam Boxer, MD, Ph.D
-
Principal Investigator:
- Howard Rosen, MD
-
-
Colorado
-
Denver, Colorado, United States, 80204
- Recruiting
- University of Colorado Denver
-
Contact:
- Danelle Carter
- Email: DANELLE.CARTER@CUANSCHUTZ.EDU
-
Principal Investigator:
- Peter Pressman, MD
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Recruiting
- Mayo Clinic Florida
-
Contact:
- Kandise Chrestensen
- Email: chrestensen.kandise@mayo.edu
-
Principal Investigator:
- Neill Graff-Radford, MD
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory University
-
Contact:
- Samantha Heldenberg
- Email: shelden@emory.edu
-
Principal Investigator:
- Chad Hales, MD
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
Principal Investigator:
- Sandra Weintraub, PhD
-
Contact:
- Caila Ryan
- Email: caila.ryan@northwestern.edu
-
Principal Investigator:
- Ian Grant, MD
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Indiana University
-
Contact:
- Ralitsa Kostadinova
- Email: rkostad@iu.edu
-
Principal Investigator:
- David Clark, MD
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Recruiting
- Johns Hopkins University
-
Contact:
- Ann Fishman
- Email: ann.fishman@jhu.edu
-
Principal Investigator:
- Chiadi Onyike, MD, MHS
-
Bethesda, Maryland, United States, 20814
- Recruiting
- NIH
-
Contact:
- Carol Hoffman
- Email: carol.hoffman@nih.gov
-
Principal Investigator:
- Allison Snyder, MD
-
Principal Investigator:
- Justin Kwan, MD
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Erin Krahn
- Email: ekrahn@mgh.harvard.edu
-
Principal Investigator:
- Brad Dickerson, MD
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- University of Michigan
-
Contact:
- Kiren Chaudhry
- Email: chaudhki@med.umich.edu
-
Principal Investigator:
- Sami Barmada, MD
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic Rochester
-
Principal Investigator:
- Bradley Boeve, MD
-
Contact:
- Abbi Osborne
- Email: osborne.abigail@mayo.edu
-
Contact:
- Shelby Heintz
- Email: heintz.shelby@mayo.edu
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washinton University in St. Louis
-
Contact:
- Tina Nolte
- Email: nolte.tina@wustl.edu
-
Principal Investigator:
- Nupur Ghoshal, MD, PhD
-
-
Nevada
-
Las Vegas, Nevada, United States, 89106
- Recruiting
- Cleveland Clinic Lou Ruvo Center for Brain Health
-
Principal Investigator:
- Dylan Wint, MD
-
Contact:
- Ghanen Concepcion
- Email: CONCEPG5@ccf.org
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- Columbia Unversity
-
Contact:
- Arlene Mejia
- Email: am4717@cumc.columbia.edu
-
Principal Investigator:
- Lawrence S Honig, MD
-
New York, New York, United States, 10029
- Not yet recruiting
- Mount Sinai
-
Contact:
- Ruth Axton
- Email: ruth.axton@mssm.edu
-
Principal Investigator:
- Fanny Elahi
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- Recruiting
- University of North Carolina, Chapel Hill
-
Principal Investigator:
- Andrea Bozoki, MD
-
Contact:
- UNC ALLFTD Team
- Email: ALLFTD@neurology.unc.edu
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Recruiting
- Case Western Reserve Medical Center
-
Contact:
- Maria Toth
- Email: maria.toth@uhhospitals.org
-
Principal Investigator:
- Brain Appleby, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania
-
Principal Investigator:
- David Irwin, MD
-
Contact:
- Julia Kwiecinski
- Email: julia.kwiecinski@pennmedicine.upenn.edu
-
-
Tennessee
-
Nashville, Tennessee, United States, 37235
- Recruiting
- Vanderbilt University
-
Contact:
- Jerica Braswell
- Email: jerica.braswell@vumc.org
-
Principal Investigator:
- Richard R Darby, MD
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- Nantz National Alzheimer Center Houston
-
Contact:
- Victoria Arbones
- Email: varbones@houstonmethodist.org
-
Principal Investigator:
- Belen Pascual, PhD
-
Principal Investigator:
- Joseph Masdeu, MD, PhD
-
San Antonio, Texas, United States, 78229
- Recruiting
- UT San Antonio Health Science Center
-
Contact:
- Crystal Mendoza
- Email: mendozac2@uthscsa.edu
-
Principal Investigator:
- A.Campbell Sullivan, PsyD, ABPP
-
-
Washington
-
Seattle, Washington, United States, 98195
- Recruiting
- University of Washington
-
Principal Investigator:
- Kimiko Domoto-Reilly, MD
-
Contact:
- Alicia Adams
- Email: adamsali@uw.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Longitudinal Arm Inclusion Criteria
Familial FTLD (f-FTLD) participants (either is acceptable):
- members of families in whom at least one member has a known disease-associated mutation in one of the major genes that cause f-FTLD: MAPT, GRN, C9orf72 (or other rare genes)
- an autosomal dominant family history of a FTLD syndrome (without a known gene) verified by medical record review or well-documented family history including family members with a medical history consistent with FTLD or a related disorder.
Sporadic FTLD (s-FTLD) participants:
Sporadic participants should be symptomatic with no known family history nor a genetic mutation indicating f-FTLD. All sporadic participants must have an FTLD syndrome as a referring diagnosis; those determined by ALLFTD clinicians to have non-FTLD diagnoses will be excluded from longitudinal visits, but their baseline visit will be included in comparative datasets. For inclusion in the longitudinal follow-up, participants should meet research criteria for one of the following FTLD syndromes:
- Progressive Supranuclear Palsy (PSP)
- Semantic variant Primary Progressive Aphasia (svPPA)
- Nonfluent variant Primary Progressive Aphasia (nfvPPA)
- Corticobasal Degeneration (CBD)/Corticobasal Syndrome (CBS)
- Behavioral variant Frontotemporal dementia (bvFTD)
- Frontotemporal Dementia with Amyotrophic Lateral Sclerosis (FTD/ALS)
Biofluid-Focused Arm Inclusion Criteria
Participants enrolled in the biofluid arm may be either f-FTLD or s-FTLD. All general inclusion criteria apply. Participants should meet research criteria (as specified above) for any FTLD syndrome or meet familial FTLD inclusion criteria. Because the biofluid arm participants do not undergo the same detailed clinical and functional assessments required for the longitudinal arm, participants may be included regardless of primary language, as long as an appropriately translated consent is available.
Exclusion Criteria:
- Known presence of a structural brain lesion (e.g. tumor, cortical infarct) that could reasonably explain symptoms in a symptomatic participant.
- Known presence of an Alzheimer's disease causing mutation in PSEN1, PSEN2 or APP; or biomarker evidence for Alzheimer's disease as a cause of the clinical syndrome.
- A previous history of Korsakoff encephalopathy, severe alcohol dependence (within 5 years of onset of dementia), frequent alcohol or other substance intoxication, or other neurological disorder.
- Evidence through history or laboratory testing of uncorrected B12 deficiency (B12 < 95% of local laboratory's normal value), unregulated hypothyroidism (TSH >150% of normal), HIV positive, renal failure (creatinine > 2), liver failure (ALT or AST > two times normal), respiratory failure that requires supplemental oxygen, large confluent white matter lesions, significant systemic medical illnesses such as deteriorating cardiovascular disease.
- Current medication likely to affect CNS functions in the opinion of the site PI.
- In the site investigator's opinion, the participant cannot complete sufficient key study procedures. The participant may be enrolled into the biofluid-focused arm if they can tolerate a blood draw and short clinical exam, but must be able to complete at least 75% of study procedures for enrollment into the longitudinal arm.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Longitudinal Arm
Annual clinic visits throughout the length of the study.
|
Biofluid-Focused Arm
Single clinic visit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Brain Volumes
Time Frame: Baseline, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year
|
Compare rates of change in whole brain and regional volumes between asymptomatic f-FTLD and symptomatic f- and s-FTLD, measured using MRI.
|
Baseline, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year
|
Change in NIH Examiner Executive Composite Score
Time Frame: Baseline, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year
|
Evaluate change in NIH Examiner Executive Composite Score in asymptomatic f-FTLD.
|
Baseline, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year
|
Change in Multidomain Impairment Rating (MIR) Scale
Time Frame: Baseline, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year
|
Annual change in MIR score (total score 0-3), which is a new global scale for FTLD that incorporates behavioral, cognitive, and motor dysfunction in the rating.
|
Baseline, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma Neurofilament Light Chain Analysis
Time Frame: 5 years
|
Annual blood samples will be collected to detect changes in plasma neurofilament light chain concentrations
|
5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Adam Boxer, MD, PhD, University of California, San Francisco
- Principal Investigator: Howie Rosen, MD, University of California, San Francisco
- Principal Investigator: Bradley Boeve, MD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Eye Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Neuromuscular Diseases
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Spinal Cord Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Tauopathies
- Cranial Nerve Diseases
- Ocular Motility Disorders
- Language Disorders
- Communication Disorders
- Paralysis
- Speech Disorders
- Ophthalmoplegia
- Sclerosis
- Motor Neuron Disease
- Amyotrophic Lateral Sclerosis
- Dementia
- Aphasia
- Frontotemporal Dementia
- Aphasia, Primary Progressive
- Pick Disease of the Brain
- Supranuclear Palsy, Progressive
- Frontotemporal Lobar Degeneration
- Corticobasal Degeneration
Other Study ID Numbers
- 19-004543
- U19AG063911 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Interested researchers must complete a data request through the ALLFTD website. All data requests will be reviewed by a committee for evaluation of scientific merit and feasibility. Please consult the website for additional information regarding this process (https://www.allftd.org/policies).
Approved requests will be delivered in a de-identified manner.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis
-
Washington University School of MedicineMassachusetts General HospitalSuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, SporadicUnited States
-
University of Sao Paulo General HospitalPontifícia Universidade Católica do ParanáUnknownAMYOTROPHIC LATERAL SCLEROSISBrazil
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
-
CytokineticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States, Netherlands, Canada, Belgium, United Kingdom, France, Germany, Ireland, Italy, Portugal, Spain
-
Columbia UniversityALS AssociationTerminatedAmyotrophic Lateral Sclerosis (ALS)United States
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedAmyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, SporadicMexico
-
University Hospital, GenevaCompletedAmyotrophic Lateral Sclerosis 11Switzerland
-
Fondazione Don Carlo Gnocchi OnlusFondazione Salvatore MaugeriCompleted